DBV Technologies SA Sponsored ADR
(NASDAQ : DBVT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.69%342.851.2%$619.74m
GILDGilead Sciences, Inc.
-0.75%72.370.9%$506.86m
CELGCelgene Corporation
-0.45%89.961.2%$494.15m
AMGNAmgen Inc.
-0.14%197.141.2%$484.65m
ILMNIllumina, Inc.
0.13%326.303.5%$374.18m
REGNRegeneron Pharmaceuticals, Inc.
-0.48%372.482.6%$314.28m
VRTXVertex Pharmaceuticals Incorporated
-1.06%174.221.9%$206.87m
ALXNAlexion Pharmaceuticals, Inc.
0.15%116.172.0%$186.86m
AAgilent Technologies, Inc.
0.11%64.731.5%$159.45m
SRPTSarepta Therapeutics, Inc.
-0.43%129.6916.6%$141.85m
NKTRNektar Therapeutics
0.43%60.295.6%$126.83m
BLUEBluebird Bio, Inc.
-0.29%157.5514.6%$121.23m
EXASExact Sciences Corporation
-0.85%48.4325.3%$117.82m
BMRNBioMarin Pharmaceutical Inc.
-2.12%98.874.4%$116.23m
INCYIncyte Corporation
-0.39%68.532.5%$111.30m

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.